| abstract |
The present invention is a method of predicting the evolution of a patient suffering of CLL comprising the steps of determining in a biological sample obtained from said patient the DNA methylation level of site cg11472422 of the lymphocyte population of said sample, comparing the result of said methylation level with a standard wherein the methylation level is indicative of a CLL outcome subgroup, and predicting the evolution of said patient evaluating the result of the comparison. In a preferred embodiment, the method comprises additionally, the determination of the methylation level of at least one site selecting from any of the following:cg03462096, cg17014214, cg00869668, cg09637172 or any combination thereof. |